- BASF granted exclusive distributorship for Xerion's proprietary technology, PUFAcoat, in major supplement markets
- PUFAcoat Omega-3 Index testing kits provide highly accurate fatty acid measurement
'BASF has consistently demonstrated leadership and dedication to personalized nutrition with strategic partners who share the same vision to deliver the right nutrients to the right people at the right time, while meeting consumer needs. Partnerships are central to our personalized nutrition strategy and this collaboration with Xerion reinforces BASF's commitment to personalized nutrition,' said François Scheffler, Senior Vice President, BASF Global Human Nutrition. 'PUFAcoat is an important innovation designed to improve the omega-3 index deficit and advance personalized nutrition in Asia Pacific and globally.'
The omega-3 index is defined as the total concentration of EPA and DHA in red blood cells, expressed as a percent of total fatty acid content. It was developed in 2011 by Professor William Harris and Professor Clemens von Schacky as one of the key biomarkers in tracking cardiovascular health. Globally, more than 17 million deaths a year are caused by cardiovascular disease, thus making it a key concern for consumers worldwide1.
Xerion's technology allows for highly accurate readings of omega-3 index, empowering consumers to make informed choices on improving their omega-3 levels by increasing their intake through food or supplements.
'We believe that partnering the PUFAcoat technology with BASF, a global leader in human nutrition, is the fastest way to address this omega-3 deficit,' said Daniel Goldman, Managing Director of Xerion Limited.
Strong scientific evidence supports the benefits of dietary EPA and DHA for maintaining and optimizing heart and metabolic health. In particular, having a higher omega-3 index has been associated with reduced risk of cardiovascular events. Knowing an individual's omega-3 levels is, therefore, fundamental to reaching the optimal concentration in the body by increasing the intake of omega-3, and thus improving cardiovascular health.
Despite being supported by robust scientific research, the omega-3 index in many parts of the world, including countries in Asia Pacific, remains low at less than 6%2. An index greater than 8% is regarded as optimal, with strong correlation to lower cardiovascular risk.
1Mozaffarian et al. 2016 Circulation 133: e38
2Stark et al. 2016 Progress in Lipid Research 63: 132-152
About BASF
About Xerion Limited
Xerion Limited is a consumer healthcare company focused on revolutionizing standard of care in dermatology through the development and commercialization of innovative therapies and diagnostics. Xerion Limited has the exclusive commercial license to the PUFAcoatTM technology developed by Professor Robert Gibson and Dr Ge Liu of the School of Agriculture, Food and Wine, University of Adelaide. The technology allows simple, accessible, personalized determination of an individual's fatty acid profile to help improve their health and achieve their wellness goals. Further information at www.xerion.com.au. PUFAcoat is a trademark owned by the University of Adelaide.
Media contact
BASF South East Asia Pte. Ltd | Xerion Limited |
Kris Lee Communications Asia Pacific, Nutrition & Health | Daniel P Goldman Managing Director |
+65 6432 3349 | +61 3 9553 8868 |
kris.lee@basf.com | dgoldman@xerion.com.au |
Attachments
- Original document
- Permalink
Disclaimer
BASF India Ltd. published this content on 14 June 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 14 June 2018 02:27:07 UTC